3results about How to "Prevent restenosis" patented technology

The utility model belongs to the technical field of medical instruments, and discloses a ureteral stent. The ureteral stent comprises a metal framework, the metal framework is of a spiral spring structure, an elastic thin film is partially or completely attached to the inner side and / or the outer side of the metal framework, the thin film is formed by covering a film when the spiral spring structure is pulled open to generate a gap, and when the spiral spring structure is released and restored to a natural state, the elastic thin film is attached to the metal framework. The thin film is extruded by the rebounded spiral spring structure, and the thin film and the metal framework are encircled to form an impermeable tube cavity. Due to the fact that the elastic thin film is attached to the inner side and / or the outer side of the metal framework, when the metal framework is stretched or compressed, complete impermeability can be kept, no gap is generated at the bending gap of the ureteral stent, ureteral wall tissue proliferative ingrowth is avoided, restenosis of the ureter is effectively avoided, and the ureteral stent has the advantages of being simple in structure and convenient to use. The clinical experience of the patient is greatly improved, and the pain is relieved.

The utility model discloses a medicine support which comprises a support body, the support body comprises a plurality of supporting frames, and every two adjacent supporting frames are connected with each other. A first open groove and a plurality of second open grooves are formed in the outer wall of the supporting frame, the supporting frame is divided into a plurality of independent areas by the first open groove and the second open grooves, and a plurality of micropores are formed in each area; the first open groove and the second open groove are filled with anti-inflammatory drugs; the micropores are filled with an anti-atherosclerosis medicine; an anti-proliferation drug is sprayed on the outer wall of the stent body, and the anti-proliferation drug covers the anti-atherosclerosis drug and the anti-inflammatory drug. Therefore, the pathological process can be accurately matched, different drugs are made to act on different time periods after the PCI operation respectively, different effects are achieved according to the pathological characteristics of the different time periods, short-term stent restenosis is prevented, and long-term stent restenosis can be effectively prevented.

This invention relates to the field of medical device manufacturing technology, and in particular to a method for preparing a composite material stent and the stent made therefrom. The method includes the following steps: Step S1, preparation of magnesium alloy tubing and initial processing of the skeleton; Step S2, surface pretreatment of the skeleton; Step S3, construction of an intermediate bonding layer; Step S4, coating with a PLLA outer layer; Step S5, molding and post-processing; Step S6, final inspection and sterilization. This invention achieves synergistically enhanced mechanical properties. The magnesium alloy core provides strong initial support, while the PLLA outer layer provides supplementary support. It also exhibits controllable degradation performance; the PLLA outer layer effectively delays the corrosion of the magnesium alloy by chloride ions and other substances in body fluids, extending the support time. The PLLA outer layer isolates the magnesium alloy from direct contact with blood, further reducing the risk of thrombosis. The specially designed intermediate bonding layer structure ensures the structural integrity of the stent during its service life.